Next Article in Journal
Genetic Risk Assessment of Nonsyndromic Cleft Lip with or without Cleft Palate by Linking Genetic Networks and Deep Learning Models
Previous Article in Journal
Probing the E1o-E2o and E1a-E2o Interactions in Binary Subcomplexes of the Human 2-Oxoglutarate Dehydrogenase and 2-Oxoadipate Dehydrogenase Complexes by Chemical Cross-Linking Mass Spectrometry and Molecular Dynamics Simulation
Previous Article in Special Issue
Topical Diacerein Decreases Skin and Splenic CD11c+ Dendritic Cells in Psoriasis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 5
10.3390/ijms24054556
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Psoriatic Resolved Skin Epidermal Keratinocytes Retain Disease-Residual Transcriptomic and Epigenomic Profiles

by
Ameneh Ghaffarinia
1,2,
Ferhan Ayaydin
3,4,5,
Szilárd Póliska
6,
Máté Manczinger
2,7,8,
Beáta Szilvia Bolla
1,2,
Lili Borbála Flink
1,2,
Fanni Balogh
1,2,9,
Zoltán Veréb
10,11,
Renáta Bozó
1,2,9,
Kornélia Szabó
1,2,9,
Zsuzsanna Bata-Csörgő
1,2,9 and
Lajos Kemény
1,2,9,*
1
HCEMM-USZ Skin Research Group, H-6720 Szeged, Hungary
2
Department of Dermatology and Allergology, Albert Szent-Györgyi Medical School, University of Szeged, H-6720 Szeged, Hungary
3
HCEMM-USZ, Functional Cell Biology and Immunology, Advanced Core Facility, H-6728 Szeged, Hungary
4
Laboratory of Cellular Imaging, Biological Research Centre, Eötvös Loránd Research Network, H-6726 Szeged, Hungary
5
Institute of Plant Biology, Biological Research Centre, H-6726 Szeged, Hungary
6
Genomic Medicine and Bioinformatics Core Facility, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary
7
Systems Immunology Research Group, Institute of Biochemistry, Biological Research Centre, ELKH, H-6726 Szeged, Hungary
8
HCEMM-Systems Immunology Research Group, H-6726 Szeged, Hungary
9
ELKH-SZTE Dermatological Research Group, Department of Dermatology and Allergology, University of Szeged, H-6720 Szeged, Hungary
10
Regenerative Medicine and Cellular Pharmacology Laboratory (HECRIN), Department of Dermatology and Allergology, University of Szeged, H-6720 Szeged, Hungary
11
Research Institute of Translational Biomedicine, Department of Dermatology and Allergology, University of Szeged, H-6720 Szeged, Hungary
 
add Show full affiliation list
 
remove Hide full affiliation list
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(5), 4556; https://doi.org/10.3390/ijms24054556
Submission received: 21 December 2022 / Revised: 17 February 2023 / Accepted: 21 February 2023 / Published: 25 February 2023
(This article belongs to the Special Issue Frontiers in Psoriasis (PsO) and Psoriatic Arthritis (PSA))
Browse Figures
Review Reports Versions Notes

Abstract

:
The disease-residual transcriptomic profile (DRTP) within psoriatic healed/resolved skin and epidermal tissue-resident memory T (TRM) cells have been proposed to be crucial for the recurrence of old lesions. However, it is unclear whether epidermal keratinocytes are involved in disease recurrence. There is increasing evidence regarding the importance of epigenetic mechanisms in the pathogenesis of psoriasis. Nonetheless, the epigenetic changes that contribute to the recurrence of psoriasis remain unknown. The aim of this study was to elucidate the role of keratinocytes in psoriasis relapse. The epigenetic marks 5-methylcytosine (5-mC) and 5-hydroxymethylcytosine (5-hmC) were visualized using immunofluorescence staining, and RNA sequencing was performed on paired never-lesional and resolved epidermal and dermal compartments of skin from psoriasis patients. We observed diminished 5-mC and 5-hmC amounts and decreased mRNA expression of the ten-eleven translocation (TET) 3 enzyme in the resolved epidermis. SAMHD1, C10orf99, and AKR1B10: the highly dysregulated genes in resolved epidermis are known to be associated with pathogenesis of psoriasis, and the DRTP was enriched in WNT, TNF, and mTOR signaling pathways. Our results suggest that epigenetic changes detected in epidermal keratinocytes of resolved skin may be responsible for the DRTP in the same regions. Thus, the DRTP of keratinocytes may contribute to site-specific local relapse.

1. Introduction

Psoriasis is a relapsing–remitting immune-mediated skin disorder characterized by epidermal hyperplasia, and massive inflammatory infiltrates as hallmarks of scaly erythematous lesions [1,2]. The global prevalence of psoriasis is around 125 million people worldwide [3]. Successful treatment of psoriasis leads to the normalization of epidermal thickness, reduced leukocyte infiltrate, and the return to a clinically and histologically normal condition [4,5,6], referred to as resolved skin. However, many patients do not attain sustained remission and often experience the reappearance of cutaneous symptoms within weeks or months of cessation of the therapy [7,8]. The psoriatic lesions frequently occur on the so-called predilection sites, such as knees and elbows, and they usually reappear on the same body parts. On the other hand, patients can also identify body regions never affected by psoriasis, which we can refer to as never-lesional skin. Previously, we showed that the psoriatic uninvolved skin in patients with severe plaque-type psoriasis maintains molecular, cellular, and extracellular alterations and displays a “pre-psoriatic” phenotype; however, in these studies, we did not discriminate between psoriatic never-lesional and resolved uninvolved skin [9,10,11,12,13]. Since disease flare-up most commonly occurs in the resolved skin, we decided to distinguish between resolved and never-lesional skin to find clues for the recurrence of the disease.
Tissue-resident memory (TRM) T cells retained in resolved skin have been suggested as the main drivers of psoriasis relapse [9,14,15,16]. However, whether structural skin cells such as epidermal keratinocytes play a role in the recurrence of the clinical symptoms or not is unclear. At the molecular level, previous bulk microarray and RNA sequencing studies have shown abnormal expression of immune and skin structural genes within resolved skin [14,15,16,17,18]. Nonetheless, it is difficult to dissect the cell-specific transcripts in a whole-skin transcriptome due to its diverse cell populations. Furthermore, it is now apparent that epigenetic regulatory mechanisms such as DNA methylation and DNA hydroxymethylation play a pivotal role in the pathogenesis of several skin diseases, such as psoriasis [19,20,21,22,23,24,25,26,27,28,29,30]. However, the epigenetic changes contributing to psoriasis relapse remain unknown.
In order to clarify the role of keratinocytes in the recurrence of lesions in resolved skin, we looked at epidermal keratinocyte transcriptomic and epigenomic differences in resolved vs. never-lesional skin. Since the specific transcripts of epidermal keratinocytes often remain masked in whole-skin transcriptomic analyses, we performed high-throughput RNA sequencing separately on the epidermal and dermal compartments. The visualization of the general pattern of DNA methylation and DNA hydroxymethylation epigenetic marks, 5-mC (5-methylcytosine) and 5-hmC (5-hydroxymethylcytosine) was performed on the paired resolved and never-lesional skin sections using immunofluorescence staining. Finally, we examined the overlap between resolved vs. never-lesional skin in terms of differentially expressed genes (DEGs) from our study, and the lesional vs. healthy skin DEGs from the available datasets.
We observed decreased contents of 5-mC and an apparent loss of 5-hmC in resolved epidermis vs. never-lesional epidermis. Additionally, the 5-hmC decreased levels were accompanied by decreased ten-eleven translocation (TET) 3 mRNA expression in resolved epidermis as compared to never-lesional epidermis. There were 102 genes that overlapped among the DEGs of resolved vs. never-lesional epidermis and lesional vs. healthy epidermis. These data suggest that epidermal keratinocytes of resolved skin may contribute to a local relapse in psoriasis, possibly because they are not epigenetically and transcriptionally fully recovered to the baseline level (never-lesional skin). The experimental workflow is summarized in Figure 1.

2. Results

2.1. 5-mC and 5-hmC Amounts Were Overall Lower in Resolved Epidermis as Compared to Never-Lesional Epidermis

Using immunofluorescence staining and confocal microscopy, we observed that 5-mC and 5-hmC amounts were overall lower in resolved epidermis as compared to never-lesional epidermis. We detected a uniform 5-mC distribution pattern in both never-lesional and resolved epidermis and enhanced 5-hmC intensity in the suprabasal layer of never-lesional vs. resolved epidermis (Figure 2a). On higher resolution images (oil immersion objective), 5-mC and 5-hmC nuclei staining were apparently weaker in the resolved epidermis compared to the never-lesional samples (Figure 2a, closeups). False-colored low-magnification images reported these findings in each patient, although a few 5-hmC hot patches were observed in the resolved epidermis (Figure 3).

2.2. 5-hmC Weaker Intensity Was Accompanied by Decreased TET3 mRNA Expression Level in Resolved Epidermis

The 5-hmC epigenetic mark is an intermediate product of active DNA demethylation. This refers to an enzymatic process in which ten-eleven translocation (TET)1, TET2, and TET3 enzymes oxidize the methyl group of 5-mC and convert it to 5-hmC [31,32]. Therefore, we analyzed mRNA expression levels of these enzymes in paired never-lesional and resolved epidermal samples to verify whether there was a link between 5-hmC loss in resolved epidermis and gene expression alterations of these enzymes. The real-time RT-PCR results showed a significant decrease in TET3 (p = 0.0002) and no changes in TET1 and TET2 mRNA expression level in resolved vs. never-lesional epidermis (Figure 2b). Overall, we observed a correlation between a 5-hmC decreased level and TET3 mRNA expression in resolved epidermis. These results are consistent with previous findings confirming that the loss of 5-hmC was associated with lower mRNA expression of TET enzymes in the epidermis of psoriatic lesions [28].

2.3. Transcriptome Profiling of the Resolved Epidermis vs. Never-Lesional Epidermis

2.3.1. Analysis of Differentially Expressed Genes (DEGs)

A pairwise comparison of RNA sequencing profiles from paired resolved and never-lesional epidermal and dermal compartments was performed to determine differences in gene expression. Transcriptome analysis of four patients samples yielded 476 DEGs in resolved epidermis vs. never-lesional epidermis (p < 0.05). Of these, 275 (≈57.77%) were down-regulated, and 201 (≈42.23%) were up-regulated. The same analysis of three patients yielded 2966 DEGs in resolved dermis vs. never-lesional dermis (p < 0.05). Of 2966 DEGs, 1360 (≈45.85%) were identified as down-regulated, and 1606 (≈54.15%) as up-regulated genes in the resolved dermis vs. never-lesional dermis. Principle component analysis (PCA) was performed using the resolved vs. never-lesional DEGs as input. The analyses showed a clear separation between all resolved and never-lesional paired samples (Figure S1a,b, see Supplementary Materials).
To narrow the search for candidate genes that may play a role in psoriatic lesion recurrence, we examined the 25 most down-regulated and up-regulated DEGs in resolved vs. never-lesional epidermal and dermal compartments (Table 1).

2.3.2. The Most Down-Regulated DEGs in Resolved Epidermis vs. Never-Lesional Epidermis (|FC| ≥ 2.5)

Overall, three genes with |FC| ≥ 2.5 were decreased in the resolved epidermis compared with the never-lesional epidermis, including nuclear enriched abundant transcript 1 conserved region 3 (NEAT1_3), sterile alpha motif and HD domain-containing protein 1 (SAMHD1), and Homeobox protein Hox-B2 (HOXB2) (Table 1). Among these, NEAT1_3 and SAMHD1 can act as inflammation regulatory genes. The NEAT1_3 gene produces a long non-coding RNA (lncRNA) with critical roles in innate immune responses [33,34,35]. Screening of the expression of some common lncRNAs in psoriasis using real-time RT-PCR has shown decreased expression of the NEAT1 gene in lesional skin compared to healthy skin [36]. The gene SAMHD1 is the only deoxynucleoside triphosphohydrolase (dNTPase) in eukaryotes, and is required for genome integrity by tightly controlling the intracellular deoxynucleoside triphosphate (dNTP) pools to prevent toxic dNTP accumulation [37]. Using RNA sequencing analyses, SAMHD1 was shown to be significantly up-regulated in psoriatic lesional skin compared to healthy skin (fold of change, 1.5) [38].

2.3.3. The Most Up-Regulated DEGs in Resolved Epidermis vs. Never-Lesional Epidermis (|FC| ≥ 2.5)

A total of six genes, including SH3 and cysteine-rich domain 2 (STAC2), aquaporin 5 (AQP5), family with sequence similarity 25 member C (FAM25C), ELOVL fatty acid Elongase 3 (ELOVL3), chromosome 10 open reading frame 99 (C10orf99), and aldo-keto reductase family 1 member B10 (AKR1B10), were increased with a change greater than 2.5-fold in resolved epidermis vs. never-lesional epidermis (Table 1). Two of these transcripts, C10orf99 and AKR1B10, were highly expressed in the lesional skin of psoriasis patients compared to healthy controls [39,40,41]. AKR1B10 is a human NADPH-dependent oxidoreductase [42]. The AKR1B10 enzyme plays a role in lipid metabolism and functions as a positive regulator of inflammation. Inhibition of AKR1B10 can suppress the inflammatory response triggered by various stressors in cellular and animal models [43,44,45,46,47]. AKR1B10 plays a role in psoriasis lesion formation by dysregulating the retinoic acid signaling pathway, thereby inducing the excessive proliferation of keratinocytes [41]. The gene C10orf99 encodes the protein GPR15L, a novel antimicrobial peptide with broad activity against various bacteria and fungi [48]. GPR15L is mainly expressed in epithelial tissues and functions as a homeostatic chemokine for recruitment of mouse dendritic epidermal T-cell into skin [49,50,51].

2.3.4. The Most Down-Regulated DEGs in Resolved Dermis vs. Never-Lesional Dermis (|FC| > 10)

Because all 25 most down-regulated and up-regulated DEGs in resolved dermis vs. never-lesional dermis had a change greater than 2.5-fold, we decided to increase the limit to ≥10 to restrict the search to the most down-regulated and up-regulated DEGs (Table 1). The most down-regulated genes in resolved dermis vs. never-lesional dermis included small proline-rich protein 4 (SPRR4), ATPase H+/K+ transporting non-gastric alpha2 subunit (ATP12A), cystatin-E/M (CST6), Small proline-rich protein 1A (SPRR1A), cysteine-rich C-Terminal 1 (CRCT1), microseminoprotein β (MSMB), keratin 34 (KRT34), and gap junction protein beta 4 (GJB4). To the best of our knowledge, only MSMB gene down-regulation has been shown to be associated with pathogenesis of psoriasis. MSMB has been previously shown to be down-regulated in the lesional skin of psoriasis patients compared to non-lesional and healthy skin [40,52,53].

2.3.5. The Most Up-Regulated DEGs in Resolved Dermis vs. Never-Lesional Dermis (|FC| > 10)

The most up-regulated genes in resolved dermis vs. never-lesional dermis were immunoglobulin heavy variable 3-7 (IGHV3-7), immunoglobulin heavy variable 3-33 (IGHV3-33), and immunoglobulin heavy joining 4 (IGHJ4) (Table 1). Interestingly, of the 25 most up-regulated DEGs in resolved dermis, 14 transcripts, accounting for 56%, were immunoglobulin coding gene segments. The high prevalence of B cell receptor gene segments in resolved vs. never-lesional dermis raises the possibility that B cells may play a role in psoriasis local relapse. However, its importance is unknown and further studies are needed to investigate the contribution of B cells to the local recurrence of psoriatic lesions.

2.3.6. Identifying Biological Processes (BPs), Molecular Functions (MFs), and Cellular Components (CCs) Enriched among the DEGs

We performed gene ontology (GO) enrichment analysis for resolved vs. never-lesional DEGs. The results showed that 75 BPs, 32 MFs, and 7 CCs were significantly overrepresented in resolved vs. never-lesional epidermis (p < 0.05). In the GO analysis of the five most significant BPs, genes were mainly associated with the following terms: regulation of protein phosphorylation, regulation of phosphorylation, regulation of stress-activated MAPK cascade, positive regulation of stress-activated MAPK cascade and secondary heart field specification. In the five most significant MFs, genes were associated with the following terms: interleukin-6 receptor binding, death receptor activity, cysteine-type endopeptidase activity involved in the apoptotic process, positive regulation of telomerase activity, and regulation of cysteine-type endopeptidase activity. Most of these responses occurred in the early endosome lumen (Figure 4).
The results in the dermal samples revealed that 37 BPs, 6 MFs, and 29 CCs were significantly overrepresented in resolved vs. never-lesional (p < 0.05). In the five most significant BPs, genes were associated with the following terms: detection of chemical stimulus, detection of stimulus involved in sensory perception, sensory perception of the chemical stimulus, G protein-coupled receptor activity, and detection of stimulus. In the most significant MF, genes were associated with transmembrane signaling receptor activity. These responses occurred mainly in the membrane-bound cell organelles (Figure S2).

2.4. Defining the Disease-Residual Transcriptomic Profile (DRTP)

To determine the disease-residual transcriptomic profile (DRTP), we examined the overlap between the DEGs of resolved vs. never-lesional skin from our study and the DEGs of the lesional vs. healthy skin from the available datasets at GEO for both epidermal and dermal compartments. Since we did not find any meaningful overlap between DEGs of the resolved vs. never-lesional dermis and DEGs of the lesional vs. healthy dermis, we focus on our results for the epidermal samples below.
Gene expression data from lesional and healthy epidermal skin samples were downloaded from the Gene Expression Omnibus (series matrix files of GSE68937 and GSE68923 datasets). A total of 4104 DEGs were identified in lesional epidermis vs. healthy epidermis. The psoriatic lesional-specific DEGs showed a 7-fold overrepresentation in resolved vs. never-lesional DEGs compared to non-DEGs of the same comparison (Fisher’s exact test p = 5 × 10−53). Overall, 102 genes overlapped between 476 DEGs of resolved vs. never-lesional and the 4104 DEGs of lesional vs. healthy in epidermal compartments. We found that 95% of these 102 overlapping genes had the same fold change direction in the two comparisons. The amount of change strongly correlated (Spearman’s rho: 0.75, p < 2.2 × 10−16); the data are shown in Figure 5.
Of these 102 overlapping genes, 67 were down-regulated, and 35 were up-regulated in the resolved epidermis (Table S1). The five most down-regulated genes were CACNA2D1, ODF3L1, WNT2, LIF, and TPPP, whereas the five most up-regulated genes were AKR1B10, FABP5, PYDC1, WNT5A, and TMEM52 (gene abbreviations are explained in Table S1). Of note, the AKR1B10 gene was the top up-regulated overlapped gene between resolved and lesional epidermis. Combined transcriptomic analysis identified the AKR1B10 gene as the most differentially expressed gene in psoriatic lesions compared to healthy skin [41]. Microarray studies showed significantly higher expression of AKR1B10 (24-fold) in psoriatic lesions compared to healthy skin [39].
In addition, we determined the function of the overlapping genes through GO enrichment analysis. The results showed 54 significant BPs (p < 0.001 and FDR < 0.2). In the five most significant BPs, the genes were associated with the following terms: cellular response to stimulus, cellular response to transforming growth factor beta stimulus, response to transforming growth factor beta, positive regulation of the biological process, and Wnt signaling pathway involved in midbrain dopaminergic neuron differentiation (Table S2).
Then, the protein–protein interaction (PPI) networks of the 102 overlapping genes were generated using the STRING database. Based on the results, the largest network (NGFRAP1-PAMR1-TRAF6-ZC3H12A-RC3H1-PAN3-TREX2) was most likely associated with TNF signaling, whereas a cluster of WNT-signaling was also evident (Figure 6).
The KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis was also performed on the 102 overlapping genes, which revealed the enrichment of the WNT and mTOR signaling pathways. Surprisingly, the overlapping genes were most significantly enriched in the basal cell carcinoma pathway (Table 2). Interestingly, the signaling pathways associated with breast cancer, gastric cancer, and hepatocellular carcinoma were also significantly up-regulated in the resolved epidermis.

3. Discussion

Over the years, many studies have provided fundamental insights into the pathogenesis of psoriasis, and the knowledge has been translated into highly effective therapies. However, pathologic changes associated with lesion recurrence are only partially understood, making it difficult to develop practical strategies to prevent frustrating psoriasis flare-ups. A psoriasis relapse is defined by the appearance of new lesions and mainly by the recurrence of old lesions. The DRTP throughout psoriatic healed skin [14,15,16,17,18] and epidermal tissue-resident memory T cells (TRMs) [9,14,15,16] have been considered critical for the recurrence of old lesions. However, the role of resolved skin epidermal keratinocytes in disease recurrence is an unresolved issue.
This is the first study to highlight the potential significance of epidermal keratinocytes in psoriasis local relapse by elucidating the DRTP and methylation/hydroxymethylation status in resolved epidermis. Our transcriptional results confirmed the distinction between transcriptomic profiles of never-lesional and resolved uninvolved skin in psoriasis. Among the DEGs in resolved epidermis compared with the never-lesional epidermis, the most down-regulated genes were functionally related to inflammation regulation (NEAT1-3) and genome integrity (SAMHD1). In addition, we found that genes involved in lipid metabolism (ELOVL3 and AKR1B10) and inflammation flare-up (C10orf99) were among the most up-regulated DEGs in resolved epidermis vs. never-lesional epidermis. Three of the most dysregulated genes, namely SAMHD1, C10orf99, and AKR1B10, were identified as likely to be important for lesion development in the resolved epidermis. We suggest these genes could confer a hypersensitivity of resolved epidermal keratinocytes to a secondary assault (Figure 7).
Since it was previously shown that SAMHD1-deficient fibroblasts from patients with Aicardi Goutières syndrome (AGS), a rare inflammatory disease, had elevated dNTP pools associated with chronic DNA damage and up-regulation of interferon (IFN)-stimulated genes [54], it is possible that SAMHD1-deficient resolved epidermal keratinocytes also have elevated dNTP levels compared to never-lesional cells, which may lead to latent and persistent DNA damage and inflammation. Thus, resolved epidermal keratinocytes may be more susceptible to genotoxic stress than never-lesional cells.
C10orf99 or GPR15L may act as a chemotactic ligand for GPR15 (G protein-coupled receptor 15). Transcriptomic studies and genomic analyses have shown that GPR15L is strongly up-regulated in the lesional skin of patients with psoriasis, atopic dermatitis, and in related animal models [26,40,55]. Single-cell RNA sequencing data showed that mainly epidermal keratinocytes express GPR15L in psoriatic lesional skin [56]. GPR15 is specifically expressed by effector/memory B cells, T cells, and regulatory T cells [50]. Whether the interaction between GPR15L and GPR15 plays a role in the initiation of psoriasis is unknown. However, higher expression of the chemotactic factor GPR15L in resolved epidermal keratinocytes may lead to retaining GPR15+ cells in resolved epidermis.
The AKR1B10 gene encodes a retinaldehyde reductase that plays a critical role in the retinoic acid (RA) or vitamin A metabolism and its activity causes decreased RA synthesis. Overexpression of AKR1B10 has been reported in patients with psoriasis [39], atopic dermatitis [57] and keloids [58]. This suggests that an imbalance in retinoic acid (RA) metabolism is a common feature of these relapsing–remitting inflammatory skin diseases, regardless of their pathological background. The lower intracellular level of RA is considered an inducing signal for cell proliferation and prohibiting for cell differentiation, both of which promote tumorigenesis in affected tissues [59]. In resolved epidermal keratinocytes, significant overexpression of AKR1B10 may decrease the level of RA by suppressing the RA synthesis pathway and increase cell survival and proliferation by activating the retinal–retinol pathway. On the other hand, the lower expression of AKR1B10 gene in never-lesional epidermal keratinocytes may increase the level of RA and induce keratinocytes differentiation while decreasing cell survival. However, the abovementioned hypotheses need to be investigated and are open to future research on psoriasis local relapse.
In addition, we defined the DRTP as a set of 102 expressed genes that overlapped between the DEGs of resolved vs. never-lesional and the DEGs of lesional vs. healthy skin. Remarkably, we found that the AKR1B10 transcript was not only among the most up-regulated DEGs in the resolved epidermis compared to the never-lesional epidermis, but was also the most up-regulated transcript overlapping between resolved and lesional epidermis. This finding suggests that the retinoic acid signaling pathway plays an essential role in the local recurrence of psoriatic lesions. Indeed, acitretin, a widely used drug for psoriasis, acts through the retinoic acid signaling pathway and affects keratinocytes proliferation and differentiation [60]. Since AKR1B10 is also a druggable target [61], the repurposing of the already known AKR1B10 inhibitors could be of translational importance.
We also found that Wnt5a, a negative regulator of epidermal keratinocyte differentiation, remained strongly up-regulated in resolved epidermal keratinocytes. This is consistent with previous findings that recognized the Wnt5a gene as DRTP in psoriatic healed skin after successful etanercept therapy [14]. Our STRING and KEGG pathway analyses also revealed the up-regulation of genes involved in the Wnt pathway. Overall, these data support the hypothesis that the WNT signaling pathway may contribute to the recurrence of psoriatic lesions. Furthermore, TNF and mTOR signaling pathways, which play a role in the pathogenesis of psoriasis, were among the major disease-residual pathways identified in our STRING and KEGG pathway analyses.
We also demonstrated a clear difference in the 5-mC and 5-hmc general pattern between psoriatic never-lesional and resolved, uninvolved skin. In resolved epidermis, in addition to 5-mC and TET3 mRNA expression levels compared with never lesional epidermis, we also found greatly decreased 5-hmC contents. Loss of 5-hmC has been reported in different solid tumors [62] and immune-mediated skin disorders, such as psoriasis [28]. Since 5-mC is the only substrate to produce 5-hmC in vivo [63], the loss of 5-hmC in resolved epidermal keratinocytes could result from a global decrease in 5-mC content. On the other hand, TET enzyme dysfunction or decreased levels of it may also result in reduced 5-hmC generation in cells. Hence, low 5-mC content and TET3 enzyme deficiency within the resolved epidermis possibly account for the loss of 5-hmC in resolved epidermal keratinocytes (Figure 8). Interestingly, perturbation of TET-5-hmC pathway in the epidermis of psoriatic lesions has been already reported. It has been suggested that this is related to the loss of the self-renewal capacity of basal keratinocytes that become FABP5-expressing transient amplifying cells (TACs) [28]. In our study, FABP5 remained up-regulated (2.09-fold) in the hypo-hydroxymethylated resolved epidermis (Table 1). These results and the disrupted Wnt5a signaling pathway in the resolved epidermis suggest that epidermal keratinocytes in healed/resolved skin harbor cell differentiation defects at the transcriptomic and epigenetic levels. As mentioned previously, we also observed that DNA was hypo-methylated in resolved epidermal keratinocytes compared to never-lesional cells. The hypo-methylated DNA profile, defined as a decreased 5-mC content of the genome, is a hallmark of several cancers [64] and autoimmune diseases [65,66,67,68,69]. It has been reported that auto-reactive T cells in systemic lupus erythematosus (SLE) [65,66], synovial fibroblasts in rheumatoid arthritis (RA) [67], and cells in the white matter of multiple sclerosis (MS) scars are globally hypo-methylated [68,69]. DNA methylation profiling in psoriasis patients showed intermediate methylation differences in psoriatic uninvolved skin compared to healthy and psoriatic lesional skin [26]. In summary, our findings suggest that disease-residual epigenomic and transcriptomic profiles are still present in resolved epidermal keratinocytes after successful therapy.

4. Materials and Methods

4.1. Psoriatic Skin Samples Collection and Ethics

Seven volunteer patients with moderate-to-severe plaque-type psoriasis, aged >25 years, were enrolled in our study. The disease severity was evaluated using the Psoriasis Area and Severity Index (PASI) scoring system. The PASI is a widely used and gold standard measurement tool that grades the severity of psoriatic lesions and assesses the treatment response of psoriasis patients [70]. This study recruited patients who matched the criteria irrespective of sex and therapeutic regimen. Our inclusion criteria were to have patients with moderate-to-severe (PASI above 15) plaque-type psoriasis before initiating systemic therapy and being on systemic therapy for at least 1 year before taking their skin samples. Psoriatic patients’ detailed information and experimental techniques applied to their samples are available in Table S3. Psoriatic tissue collection was obtained after written informed consent according to the rules of the Helsinki Declaration. Protocols for obtaining patient biopsies were approved by the Regional and Institutional Research Ethics Committee (PSO-CELL-01, 90/2021, 4969, 26 April 2021, Szeged, Hungary; HCEMM-001, 10/2020, 4702, 20 January 2020, Szeged, Hungary) for the protection of human subjects. Full-thickness 6 mm paired never-lesional and resolved skin punch biopsies (PBs) were taken under aseptic conditions with local anesthesia from psoriasis patients. At the time of sampling, their resolved skin had been resolved for at least 6 months. Both the clinician and the patient determined the resolved skin, and the lesional skin was obvious to detect.

4.2. Co-Localization of 5-mC and 5-hmC Epigenetic Marks in Psoriatic Never-Lesional and Resolved Skin Sections

First, we set up the protocol for equilibrium binding of 5-mC and 5-hmC antibodies to the target antigens in frozen paraformaldehyde-fixed healthy skin sections (Appendix A). Shortly, never-lesional and resolved skin PBs were immediately fixed in a freshly made 4% paraformaldehyde (PFA 4%) solution in PBS (containing 0.01% TritonX-100) for 6 h on a rocker at room temperature (RT). Then the samples were washed once with PBS for 5 min. To minimize freezing-induced damages, the samples were infused gradually with sucrose by placing them in 10% and 20% sucrose in PBS (1 h each by rocking at RT) and 30% sucrose (overnight at 4 °C) [71]. The tissues were subsequently frozen in the cryogenic matrix (Thermo Fisher Scientific, Waltham, MA, USA) using liquid nitrogen, and 12 μm sections were cut and stored at −20 °C until further processing. The sections were washed 2 × 15 min in PBS to remove the infused sucrose and were incubated for 10 min in 0.1% Triton X-100 in PBS at RT. For antigen retrieval, sections were incubated for 1 h with freshly made 2 N hydrochloric acid (HCl) in PBS at RT. After DNA denaturation, sections were neutralized using 0.1 M Tris-HCl (pH 8.3) for 10 min. For blocking, the sections were incubated in blocking solution ((1% normal goat serum, 1% bovine serum albumin (Sigma-Aldrich, St. Louis, MO, USA) in PBS)) for 1 h, at RT in a humidified chamber. Samples were incubated with the following primary antibodies: polyclonal rabbit anti-human 5-hmC (1:1000, Active motif, Carlsbad, CA, USA, Cat No. 39769), mouse monoclonal anti-human 5-mC (1:500, Epigentek, East Farmingdale, NY, USA, Cat No. A-1014) for over-night at 4 °C. Purified mouse IgG1 κ isotype (Biolegend, San Diego, CA, USA, Cat No. 400102) was used for 5-mC isotypic control. As secondary antibodies, AlexaFluor 546-conjugated anti-rabbit IgG and AlexaFluor 647-conjugated anti-mouse IgG (Life Technologies, Carlsbad, CA) were used (both 1:500). We visualized the nuclei with DAPI (Sigma-Aldrich, St. Louis, MO, USA) staining.

4.3. Microscopy

Olympus Fluoview FV1000 (Olympus Life Science Europa GmbH, Hamburg, Germany) confocal laser scanning microscope was used for fluorescence imaging following immunolocalization. Dry (10×, 20×) and oil immersion (PLANAPO 40× and 60×) objectives were used during imaging. The default DAPI and AlexaFluor dye combination setup of the microscope was used to capture images. Transmitted light detector of the microscopes were used for bright field images and merged onto DAPI images using Olympus Fluoview software. As regards Figure 3, identical microscope configuration is used for all intensity comparison images where ICA look up table of FIJI open software was employed after identical enhancing of brightness values of never-lesional and resolved pairs [72].

4.4. RNA Extraction and Real-Time RT-PCR

The skin PBs were washed in cold saline containing antibiotic/antimycotic (AB/AM) to remove the blood. Subsequently, the skin PBs were incubated in Dispase II solution (neutral protease, grade II, 2 U/mL, Roche Diagnostics, Basel, Switzerland) for 3 h at 37 °C and the epidermis was then carefully peeled from the dermis [73]. Following that, the epidermal and dermal compartments were immediately submerged in RNAlater (Invitrogen, Waltham, MA, USA, Cat No. AM7020) for storage until further processing for RNA extraction. Only the Ustekinumab-treated patients were included for full-length transcriptome sequencing (Table S3). Epidermal and dermal samples were mechanically homogenized using the Ultra Turrax T8 homogenizer (IKA-WERKE, Staufen, Germany). Total RNA was extracted using TRI-Reagent (Molecular Research Center; Cincinnati, OH, USA). The purity and concentration of RNA samples were determined via Nanodrop (Colibri Mikrovolüm Spektrometre, Berthold, Germany). The qualified RNA samples were used for cDNA synthesis using UltraScript cDNA Synthesis Kit (Thermofisher, Waltham, MA, USA). Changes in mRNA expression were detected with real-time RT-PCR using the FAM dye-labeled TaqManTM probes (Thermofisher, Waltham, MA, USA). TaqManTM probes used in our study are listed in Table S4. Real-time RT-PCR experiments were carried out using the qPCRBIO Probe Mix Lo-ROX (PCR Biosystem Ltd., London, UK) on a C1000 Touch Thermal Cycler (Bio-Rad Laboratories, Hercules, CA, USA). All reactions were duplicated, and the data were normalized to the 18S ribosomal RNA gene. Relative mRNA expression was calculated using the ΔΔCt method. Data from never-lesional and resolved epidermis were compared using an unpaired two-tailed t-test. Differences were considered significant when p < 0.05.

4.5. High-Throughput mRNA Sequencing

A high-throughput mRNA sequencing analysis was performed on the Illumina sequencing platform to obtain global transcriptome data. Total RNA sample quality was checked on Agilent BioAnalyzer using the Eukaryotic Total RNA Nano Kit according to the manufacturer’s protocol. Samples with RNA integrity number (RIN) value > 7 were chosen for the library preparation process. RNA sequencing libraries were prepared from total RNA using an Ultra II RNA Sample Prep kit (New England BioLabs, Ipswich, MA, USA) according to the manufacturer’s protocol. Briefly, poly-A RNAs were captured by oligo-dT conjugated magnetic beads and the mRNAs were then eluted and fragmented at 94 °C. First-strand cDNA was generated through random priming reverse transcription, and double-stranded cDNA was developed after the second-strand synthesis step. After repairing ends, A-tailing, and adapter ligation steps, adapter-ligated fragments were amplified in enrichment PCR; finally, sequencing libraries were generated. Sequencing runs were executed on Illumina NextSeq 500 instrument using single-end 75-cycle sequencing.

4.5.1. RNA Sequencing Data Analysis

Raw sequencing data (fastq) were aligned to human reference genome version GRCh38 using the HISAT2 algorithm, and BAM files were generated. Downstream analysis was performed using StrandNGS software (www.strand-ngs.com, The access date was 8 May 2022). BAM files were imported into the software, and the DESeq algorithm was used for normalization. Moderated t-test was used to determine DEGs in resolved versus never-lesional skin. Genes with p < 0.05 were considered DEGs. Raw sequencing data is available in the NCBI under the BioProject ID: PRJNA938026 (https://www.ncbi.nlm.nih.gov/sra/PRJNA938026, accessed on 20 December 2022).

4.5.2. Pathway Analyses

Cytoscape v3.4 software with ClueGo v2.3.5. application was used for identifying over-represented gene ontology (GO) terms. A two-sided hypergeometric test with Benjamini–Hochberg FDR correction was performed using the list of DEGs and the GO biological process database.

4.6. Examining the Overlap between Resolved vs. Never-Lesional DEGs and Lesional vs. Healthy DEGs

Gene expression data of psoriatic and healthy epidermis samples were downloaded from Gene Expression Omnibus (series matrix files of GSE68937 and GSE68923 datasets). GSE68937 and GSE68923 contained the microarray results from two models, including three lesional and two healthy epidermis samples in sets one and three lesional and three healthy epidermis samples in set 2 [74]. Differentially expressed genes between lesional and healthy epidermal samples were identified using Wilcoxon’s rank-sum test. p values were adjusted according to Benjamini and Hochberg [75], and genes with a false discovery rate lower than 0.1 (FDR < 0.1) were classified as DEGs. IDs were collated using data from the Human Gene Nomenclature Organization (HUGO) website. Fold change values were calculated by dividing the median gene expression values in psoriatic with the ones in healthy samples. The overlapping gene function was identified with a GO enrichment analysis using the GOrilla software [76,77]. We classified overlapping DEGs as target genes and all DEGs identified in resolved as background genes. Biological processes with p < 0.001 and FDR < 0.2 were considered significant. KEGG pathway enrichment analysis was carried out with WebGestalt online tool. The classification of genes was the same as for the study with GOrilla. Pathways with an FDR < 0.2 were considered significantly enriched. PPI networks were generated with STRING v11.5 using default parameters and at least medium confidence interactions. R program (version R 3.6.3) was used for statistical analyses.

4.7. Statistical Analysis

Statistical analyses and the graphs for the real-time RT-PCR results were performed using GraphPad Prism 8.0.2 (GraphPad Software, San Diego, CA, USA).

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms24054556/s1.

Author Contributions

Conceptualization, L.K. and A.G.; methodology, A.G., F.A., B.S.B., L.B.F. and F.B.; software, S.P. and M.M.; validation, L.K., F.A., S.P. and M.M.; formal analysis, S.P., M.M. and A.G.; investigation, A.G. and L.K.; writing—original draft preparation, A.G.; writing—review and editing, L.K., Z.B.-C., K.S., R.B. and Z.V.; supervision, L.K.; project administration, L.K.; funding acquisition, L.K., Z.B.-C. and K.S. All authors have read and agreed to the published version of the manuscript.

Funding

The project has received funding from the EU’s Horizon 2020 research and innovation program under grant agreement No. 739593 to L.K., and from the national research, development and innovation office Hungarian scientific research funds No. K135084 to Z.B.-C., and No. K143576 to K.S.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Regional and Institutional Research Ethics Committee (PSO-CELL-01, 90/2021, 4969, 26 April 2021, Szeged, Hungary; HCEMM-001, 10/2020, 4702, 20 January 2020, Szeged, Hungary) for the protection of human subjects.

Informed Consent Statement

Informed consent was obtained from all patients in this study.

Data Availability Statement

Data are presented in the manuscript and are available upon request from the corresponding author.

Acknowledgments

The authors sincerely thank all the participating patients for donating their valuable skin samples, Róbert Kui, Géza Róbert Nagy and Katalin Glasenhardt for their generous help and support in recruiting the patients and providing their samples, and Mónika Kohajda for her excellent technical assistance.

Conflicts of Interest

The authors declare no conflict of interest.

Appendix A

Since 5-mC and 5-hmC epitopes are usually masked within the double-stranded DNA helix, the critical step is the optimization of DNA denaturation by acid treatment (HCl, hydrochloric acid) to expose the epitopes. Accordingly, the tissue sections were subjected to HCl 1N or 2N for 30 min/1 h at 37 °C/room temperature (RT). We observed that HCl 2N treatment for 1 h at RT was optimum for denaturing DNA and exposing 5-mC/5-hmC epitopes for skin tissue sections.

References

  1. Billi, A.C.; Gudjonsson, J.E.; Voorhees, J.J. Psoriasis: Past, Present, and Future. J. Investig. Dermatol. 2019, 139, e133–e142. [Google Scholar] [CrossRef] [PubMed]
  2. Owczarek, W.; Dzik, M.; Narbutt, J.; Walecka, I.; Kowalczyk, M. Real-world evidence on time to relapse of plaque psoriasis after discontinuation of biologic treatment in Poland. Dermatol. Ther. 2021, 34, e15052. [Google Scholar] [CrossRef] [PubMed]
  3. Bu, J.; Ding, R.; Zhou, L.; Chen, X.; Shen, E. Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Front. Immunol. 2022, 13, 880201. [Google Scholar] [CrossRef] [PubMed]
  4. Chamian, F.; Lowes, M.A.; Lin, S.-L.; Lee, E.; Kikuchi, T.; Gilleaudeau, P.; Sullivan-Whalen, M.; Cardinale, I.; Khatcherian, A.; Novitskaya, I.; et al. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc. Natl. Acad. Sci. USA 2005, 102, 2075–2080. [Google Scholar] [CrossRef] [Green Version]
  5. Zaba, L.C.; Cardinale, I.; Gilleaudeau, P.; Sullivan-Whalen, M.; Suárez-Fariñas, M.; Suárez Fariñas, M.; Fuentes-Duculan, J.; Novitskaya, I.; Khatcherian, A.; Bluth, M.J.; et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 2007, 204, 3183–3194. [Google Scholar] [CrossRef]
  6. Dattola, A.; Silvestri, M.; Bennardo, L.; Passante, M.; Rizzuto, F.; Dastoli, S.; Patruno, C.; Bianchi, L.; Nisticò, S.P. A novel vehicle for the treatment of psoriasis. Dermatol. Ther. 2020, 33, e13185. [Google Scholar] [CrossRef] [Green Version]
  7. Nast, A.; Gisondi, P.; Ormerod, A.D.; Saiag, P.; Smith, C.; Spuls, P.I.; Arenberger, P.; Bachelez, H.; Barker, J.; Dauden, E.; et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris–Update 2015–Short version–EDF in cooperation with EADV and IPC. J. Eur. Acad. Dermatol. Venereol. JEADV 2015, 29, 2277–2294. [Google Scholar] [CrossRef] [Green Version]
  8. Langley, R.G.B.; Krueger, G.G.; Griffiths, C.E.M. Psoriasis: Epidemiology, clinical features, and quality of life. Ann. Rheum. Dis. 2005, 64 (Suppl. S2), ii18–i23; discussion ii24–ii25. [Google Scholar] [CrossRef] [Green Version]
  9. Szabó, K.; Bata-Csörgő, Z.; Dallos, A.; Bebes, A.; Francziszti, L.; Dobozy, A.; Kemény, L.; Széll, M. Regulatory networks contributing to psoriasis susceptibility. Acta Derm. Venereol. 2014, 94, 380–385. [Google Scholar] [CrossRef] [Green Version]
  10. Bozó, R.; Danis, J.; Flink, L.B.; Vidács, D.L.; Kemény, L.; Bata-Csörgő, Z. Stress-Related Regulation Is Abnormal in the Psoriatic Uninvolved Skin. Life 2021, 11, 599. [Google Scholar] [CrossRef]
  11. Bozó, R.; Szél, E.; Danis, J.; Gubán, B.; Bata-Csörgő, Z.; Szabó, K.; Kemény, L.; Groma, G. Cartilage Oligomeric Matrix Protein Negatively Influences Keratinocyte Proliferation via α5β1-Integrin: Potential Relevance of Altered Cartilage Oligomeric Matrix Protein Expression in Psoriasis. J. Investig. Dermatol. 2020, 140, 1733–1742.e7. [Google Scholar] [CrossRef]
  12. Bata-Csorgo, Z.; Hammerberg, C.; Voorhees, J.J.; Cooper, K.D. Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. J. Clin. Investig. 1995, 95, 317–327. [Google Scholar] [CrossRef] [Green Version]
  13. Széll, M.; Bata-Csörgo, Z.; Koreck, A.; Pivarcsi, A.; Polyánka, H.; Szeg, C.; Gaál, M.; Dobozy, A.; Kemény, L. Proliferating keratinocytes are putative sources of the psoriasis susceptibility-related EDA+ (extra domain A of fibronectin) oncofetal fibronectin. J. Investig. Dermatol. 2004, 123, 537–546. [Google Scholar] [CrossRef] [PubMed]
  14. Suárez-Fariñas, M.; Fuentes-Duculan, J.; Lowes, M.A.; Krueger, J.G. Resolved psoriasis lesions retain expression of a subset of disease-related genes. J. Investig. Dermatol. 2011, 131, 391–400. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Brodmerkel, C.; Li, K.; Garcet, S.; Hayden, K.; Chiricozzi, A.; Novitskaya, I.; Fuentes-Duculan, J.; Suarez-Farinas, M.; Campbell, K.; Krueger, J.G. Modulation of inflammatory gene transcripts in psoriasis vulgaris: Differences between ustekinumab and etanercept. J. Allergy Clin. Immunol. 2019, 143, 1965–1969. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Visvanathan, S.; Baum, P.; Vinisko, R.; Schmid, R.; Flack, M.; Lalovic, B.; Kleiner, O.; Fuentes-Duculan, J.; Garcet, S.; Davis, J.W.; et al. Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab. J. Allergy Clin. Immunol. 2019, 143, 2158–2169. [Google Scholar] [CrossRef] [Green Version]
  17. Sofen, H.; Smith, S.; Matheson, R.T.; Leonardi, C.L.; Calderon, C.; Brodmerkel, C.; Li, K.; Campbell, K.; Marciniak, S.J.; Wasfi, Y.; et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J. Allergy Clin. Immunol. 2014, 133, 1032–1040. [Google Scholar] [CrossRef] [Green Version]
  18. Kulig, P.; Musiol, S.; Freiberger, S.N.; Schreiner, B.; Gyülveszi, G.; Russo, G.; Pantelyushin, S.; Kishihara, K.; Alessandrini, F.; Kündig, T.; et al. IL-12 protects from psoriasiform skin inflammation. Nat. Commun. 2016, 7, 13466. [Google Scholar] [CrossRef] [Green Version]
  19. Ruchusatsawat, K.; Wongpiyabovorn, J.; Shuangshoti, S.; Hirankarn, N.; Mutirangura, A. SHP-1 promoter 2 methylation in normal epithelial tissues and demethylation in psoriasis. J. Mol. Med. Berl. Ger. 2006, 84, 175–182. [Google Scholar] [CrossRef] [PubMed]
  20. Chen, M.; Chen, Z.-Q.; Cui, P.-G.; Yao, X.; Li, Y.-M.; Li, A.-S.; Gong, J.-Q.; Cao, Y.-H. The methylation pattern of p16INK4a gene promoter in psoriatic epidermis and its clinical significance. Br. J. Dermatol. 2008, 158, 987–993. [Google Scholar] [CrossRef] [PubMed]
  21. Bai, J.; Liu, Z.; Xu, Z.; Ke, F.; Zhang, L.; Zhu, H.; Lou, F.; Wang, H.; Fei, Y.; Shi, Y.-L.; et al. Epigenetic downregulation of SFRP4 contributes to epidermal hyperplasia in psoriasis. J. Immunol. 2015, 194, 4185–4198. [Google Scholar] [CrossRef] [Green Version]
  22. Ruchusatsawat, K.; Wongpiyabovorn, J.; Protjaroen, P.; Chaipipat, M.; Shuangshoti, S.; Thorner, P.S.; Mutirangura, A. Parakeratosis in skin is associated with loss of inhibitor of differentiation 4 via promoter methylation. Hum. Pathol. 2011, 42, 1878–1887. [Google Scholar] [CrossRef] [PubMed]
  23. Gu, X.; Boldrup, L.; Coates, P.J.; Fahraeus, R.; Nylander, E.; Loizou, C.; Olofsson, K.; Norberg-Spaak, L.; Gärskog, O.; Nylander, K. Epigenetic regulation of OAS2 shows disease-specific DNA methylation profiles at individual CpG sites. Sci. Rep. 2016, 6, 32579. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Zhang, P.; Su, Y.; Chen, H.; Zhao, M.; Lu, Q. Abnormal DNA methylation in skin lesions and PBMCs of patients with psoriasis vulgaris. J. Dermatol. Sci. 2010, 60, 40–42. [Google Scholar] [CrossRef] [PubMed]
  25. Yooyongsatit, S.; Ruchusatsawat, K.; Noppakun, N.; Hirankarn, N.; Mutirangura, A.; Wongpiyabovorn, J. Patterns and functional roles of LINE-1 and Alu methylation in the keratinocyte from patients with psoriasis vulgaris. J. Hum. Genet. 2015, 60, 349–355. [Google Scholar] [CrossRef] [PubMed]
  26. Roberson, E.D.O.; Liu, Y.; Ryan, C.; Joyce, C.E.; Duan, S.; Cao, L.; Martin, A.; Liao, W.; Menter, A.; Bowcock, A.M. A subset of methylated CpG sites differentiate psoriatic from normal skin. J. Investig. Dermatol. 2012, 132, 583–592. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Zhang, P.; Zhao, M.; Liang, G.; Yin, G.; Huang, D.; Su, F.; Zhai, H.; Wang, L.; Su, Y.; Lu, Q. Whole-genome DNA methylation in skin lesions from patients with psoriasis vulgaris. J. Autoimmun. 2013, 41, 17–24. [Google Scholar] [CrossRef]
  28. Li, F.; Yuan, C.W.; Xu, S.; Zu, T.; Woappi, Y.; Lee, C.A.A.; Abarzua, P.; Wells, M.; Ramsey, M.R.; Frank, N.Y.; et al. Loss of the Epigenetic Mark 5-hmC in Psoriasis: Implications for Epidermal Stem Cell Dysregulation. J. Investig. Dermatol. 2020, 140, 1266–1275.e3. [Google Scholar] [CrossRef]
  29. Gu, X.; Nylander, E.; Coates, P.J.; Fahraeus, R.; Nylander, K. Correlation between Reversal of DNA Methylation and Clinical Symptoms in Psoriatic Epidermis Following Narrow-Band UVB Phototherapy. J. Investig. Dermatol. 2015, 135, 2077–2083. [Google Scholar] [CrossRef] [Green Version]
  30. Zhou, F.; Wang, W.; Shen, C.; Li, H.; Zuo, X.; Zheng, X.; Yue, M.; Zhang, C.; Yu, L.; Chen, M.; et al. Epigenome-Wide Association Analysis Identified Nine Skin DNA Methylation Loci for Psoriasis. J. Investig. Dermatol. 2016, 136, 779–787. [Google Scholar] [CrossRef] [Green Version]
  31. Wu, H.; Zhang, Y. Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev. 2011, 25, 2436–2452. [Google Scholar] [CrossRef] [Green Version]
  32. Guo, J.U.; Su, Y.; Zhong, C.; Ming, G.; Song, H. Emerging roles of TET proteins and 5-hydroxymethylcytosines in active DNA demethylation and beyond. Cell Cycle Georget. Tex 2011, 10, 2662–2668. [Google Scholar] [CrossRef] [Green Version]
  33. Carpenter, S.; Aiello, D.; Atianand, M.K.; Ricci, E.P.; Gandhi, P.; Hall, L.L.; Byron, M.; Monks, B.; Henry-Bezy, M.; Lawrence, J.B.; et al. A long noncoding RNA mediates both activation and repression of immune response genes. Science 2013, 341, 789–792. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Prinz, F.; Kapeller, A.; Pichler, M.; Klec, C. The Implications of the Long Non-Coding RNA NEAT1 in Non-Cancerous Diseases. Int. J. Mol. Sci. 2019, 20, 627. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Zhang, P.; Cao, L.; Zhou, R.; Yang, X.; Wu, M. The lncRNA Neat1 promotes activation of inflammasomes in macrophages. Nat. Commun. 2019, 10, 1495. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Gupta, R.; Ahn, R.; Lai, K.; Mullins, E.; Debbaneh, M.; Dimon, M.; Arron, S.; Liao, W. Landscape of Long Noncoding RNAs in Psoriatic and Healthy Skin. J. Investig. Dermatol. 2016, 136, 603–609. [Google Scholar] [CrossRef] [Green Version]
  37. Lee, E.J.; Seo, J.H.; Park, J.-H.; Vo, T.T.L.; An, S.; Bae, S.-J.; Le, H.; Lee, H.S.; Wee, H.-J.; Lee, D.; et al. SAMHD1 acetylation enhances its deoxynucleotide triphosphohydrolase activity and promotes cancer cell proliferation. Oncotarget 2017, 8, 68517–68529. [Google Scholar] [CrossRef] [PubMed]
  38. Raposo, R.A.; Gupta, R.; Abdel-Mohsen, M.; Dimon, M.; Debbaneh, M.; Jiang, W.; York, V.A.; Leadabrand, K.S.; Brown, G.; Malakouti, M.; et al. Antiviral gene expression in psoriasis. J. Eur. Acad. Dermatol. Venereol. JEADV 2015, 29, 1951–1957. [Google Scholar] [CrossRef] [Green Version]
  39. Sumantran, V.N.; Mishra, P.; Bera, R.; Sudhakar, N. Microarray Analysis of Differentially-Expressed Genes Encoding CYP450 and Phase II Drug Metabolizing Enzymes in Psoriasis and Melanoma. Pharmaceutics 2016, 8, 4. [Google Scholar] [CrossRef] [Green Version]
  40. Gudjonsson, J.E.; Ding, J.; Johnston, A.; Tejasvi, T.; Guzman, A.M.; Nair, R.P.; Voorhees, J.J.; Abecasis, G.R.; Elder, J.T. Assessment of the psoriatic transcriptome in a large sample: Additional regulated genes and comparisons with in vitro models. J. Investig. Dermatol. 2010, 130, 1829–1840. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  41. Gao, Y.; Yi, X.; Ding, Y. Combined Transcriptomic Analysis Revealed AKR1B10 Played an Important Role in Psoriasis through the Dysregulated Lipid Pathway and Overproliferation of Keratinocyte. BioMed Res. Int. 2017, 2017, 8717369. [Google Scholar] [CrossRef]
  42. Cao, D.; Fan, S.T.; Chung, S.S. Identification and characterization of a novel human aldose reductase-like gene. J. Biol. Chem. 1998, 273, 11429–11435. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Ramana, K.V.; Bhatnagar, A.; Srivastava, S.K. Inhibition of aldose reductase attenuates TNF-alpha-induced expression of adhesion molecules in endothelial cells. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2004, 18, 1209–1218. [Google Scholar] [CrossRef]
  44. Yadav, U.C.S.; Mishra, R.; Aguilera-Aguirre, L.; Sur, S.; Bolodgh, I.; Ramana, K.V.; Srivatsava, S.K. Prevention of allergic rhinitis by aldose reductase inhibition in a murine model. Inflamm. Allergy Drug Targets 2013, 12, 178–186. [Google Scholar] [CrossRef] [PubMed]
  45. Pladzyk, A.; Reddy, A.B.M.; Yadav, U.C.S.; Tammali, R.; Ramana, K.V.; Srivastava, S.K. Inhibition of aldose reductase prevents lipopolysaccharide-induced inflammatory response in human lens epithelial cells. Investig. Ophthalmol. Vis. Sci. 2006, 47, 5395–5403. [Google Scholar] [CrossRef] [Green Version]
  46. Srivastava, S.K.; Yadav, U.C.S.; Reddy, A.B.M.; Saxena, A.; Tammali, R.; Shoeb, M.; Ansari, N.H.; Bhatnagar, A.; Petrash, M.J.; Srivastava, S.; et al. Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. Chem. Biol. Interact. 2011, 191, 330–338. [Google Scholar] [CrossRef] [Green Version]
  47. Yadav, U.C.S.; Ramana, K.V.; Srivastava, S.K. Aldose reductase inhibition suppresses airway inflammation. Chem. Biol. Interact. 2011, 191, 339–345. [Google Scholar] [CrossRef] [Green Version]
  48. Yang, M.; Tang, M.; Ma, X.; Yang, L.; He, J.; Peng, X.; Guo, G.; Zhou, L.; Luo, N.; Yuan, Z.; et al. AP-57/C10orf99 is a new type of multifunctional antimicrobial peptide. Biochem. Biophys. Res. Commun. 2015, 457, 347–352. [Google Scholar] [CrossRef]
  49. Suply, T.; Hannedouche, S.; Carte, N.; Li, J.; Grosshans, B.; Schaefer, M.; Raad, L.; Beck, V.; Vidal, S.; Hiou-Feige, A.; et al. A natural ligand for the orphan receptor GPR15 modulates lymphocyte recruitment to epithelia. Sci. Signal. 2017, 10, eaal0180. [Google Scholar] [CrossRef]
  50. Ocón, B.; Pan, J.; Dinh, T.T.; Chen, W.; Ballet, R.; Bscheider, M.; Habtezion, A.; Tu, H.; Zabel, B.A.; Butcher, E.C. A Mucosal and Cutaneous Chemokine Ligand for the Lymphocyte Chemoattractant Receptor GPR15. Front. Immunol. 2017, 8, 1111. [Google Scholar] [CrossRef] [Green Version]
  51. Lahl, K.; Sweere, J.; Pan, J.; Butcher, E. Orphan chemoattractant receptor GPR15 mediates dendritic epidermal T-cell recruitment to the skin. Eur. J. Immunol. 2014, 44, 2577–2581. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Suárez-Fariñas, M.; Li, K.; Fuentes-Duculan, J.; Hayden, K.; Brodmerkel, C.; Krueger, J.G. Expanding the psoriasis disease profile: Interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J. Investig. Dermatol. 2012, 132, 2552–2564. [Google Scholar] [CrossRef] [Green Version]
  53. Rønholt, K.; Nielsen, A.L.-L.; Johansen, C.; Vestergaard, C.; Fauerbye, A.; López-Vales, R.; Dinarello, C.A.; Iversen, L. IL-37 Expression Is Downregulated in Lesional Psoriasis Skin. ImmunoHorizons 2020, 4, 754–761. [Google Scholar] [CrossRef] [PubMed]
  54. Kretschmer, S.; Wolf, C.; König, N.; Staroske, W.; Guck, J.; Häusler, M.; Luksch, H.; Nguyen, L.A.; Kim, B.; Alexopoulou, D.; et al. SAMHD1 prevents autoimmunity by maintaining genome stability. Ann. Rheum. Dis. 2015, 74, e17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Guo, P.; Luo, Y.; Mai, G.; Zhang, M.; Wang, G.; Zhao, M.; Gao, L.; Li, F.; Zhou, F. Gene expression profile based classification models of psoriasis. Genomics 2014, 103, 48–55. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Tseng, P.-Y.; Hoon, M.A. GPR15L is an epithelial inflammation-derived pruritogen. Sci. Adv. 2022, 8, eabm7342. [Google Scholar] [CrossRef]
  57. Ghosh, D.; Ding, L.; Sivaprasad, U.; Geh, E.; Biagini Myers, J.; Bernstein, J.A.; Khurana Hershey, G.K.; Mersha, T.B. Multiple Transcriptome Data Analysis Reveals Biologically Relevant Atopic Dermatitis Signature Genes and Pathways. PLoS ONE 2015, 10, e0144316. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  58. Jumper, N.; Hodgkinson, T.; Arscott, G.; Har-Shai, Y.; Paus, R.; Bayat, A. The Aldo-Keto Reductase AKR1B10 Is Up-Regulated in Keloid Epidermis, Implicating Retinoic Acid Pathway Dysregulation in the Pathogenesis of Keloid Disease. J. Investig. Dermatol. 2016, 136, 1500–1512. [Google Scholar] [CrossRef]
  59. Ruiz, F.X.; Porté, S.; Parés, X.; Farrés, J. Biological role of aldo-keto reductases in retinoic Acid biosynthesis and signaling. Front. Pharmacol. 2012, 3, 58. [Google Scholar] [CrossRef] [Green Version]
  60. Geiger, J.M. Efficacy of acitretin in severe psoriasis. Skin Ther. Lett. 2003, 8, 1–3, 7. [Google Scholar]
  61. Huang, L.; He, R.; Luo, W.; Zhu, Y.-S.; Li, J.; Tan, T.; Zhang, X.; Hu, Z.; Luo, D. Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment. Recent Pat. Anticancer Drug Discov. 2016, 11, 184–196. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  62. Lian, C.G.; Xu, Y.; Ceol, C.; Wu, F.; Larson, A.; Dresser, K.; Xu, W.; Tan, L.; Hu, Y.; Zhan, Q.; et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012, 150, 1135–1146. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Ficz, G.; Gribben, J.G. Loss of 5-hydroxymethylcytosine in cancer: Cause or consequence? Genomics 2014, 104, 352–357. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Ehrlich, M. DNA methylation in cancer: Too much, but also too little. Oncogene 2002, 21, 5400–5413. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Hedrich, C.M.; Mäbert, K.; Rauen, T.; Tsokos, G.C. DNA methylation in systemic lupus erythematosus. Epigenomics 2017, 9, 505–525. [Google Scholar] [CrossRef]
  66. Zhou, Y.; Lu, Q. DNA methylation in T cells from idiopathic lupus and drug-induced lupus patients. Autoimmun. Rev. 2008, 7, 376–383. [Google Scholar] [CrossRef]
  67. Karouzakis, E.; Gay, R.E.; Michel, B.A.; Gay, S.; Neidhart, M. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2009, 60, 3613–3622. [Google Scholar] [CrossRef] [Green Version]
  68. Moscarello, M.A.; Brady, G.W.; Fein, D.B.; Wood, D.D.; Cruz, T.F. The role of charge microheterogeneity of basic protein in the formation and maintenance of the multilayered structure of myelin: A possible role in multiple sclerosis. J. Neurosci. Res. 1986, 15, 87–99. [Google Scholar] [CrossRef] [PubMed]
  69. Moscarello, M.A.; Wood, D.D.; Ackerley, C.; Boulias, C. Myelin in multiple sclerosis is developmentally immature. J. Clin. Investig. 1994, 94, 146–154. [Google Scholar] [CrossRef]
  70. Gerdes, S.; Körber, A.; Biermann, M.; Karnthaler, C.; Reinhardt, M. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life. J. Dermatol. Treat. 2020, 31, 470–475. [Google Scholar] [CrossRef]
  71. Singh, R.K.; Diaz, P.E.; Binette, F.; Nasonkin, I.O. Immunohistochemical Detection of 5-Methylcytosine and 5-Hydroxymethylcytosine in Developing and Postmitotic Mouse Retina. J. Vis. Exp. JoVE 2018, 138, e58274. [Google Scholar] [CrossRef] [Green Version]
  72. Schindelin, J.; Arganda-Carreras, I.; Frise, E.; Kaynig, V.; Longair, M.; Pietzsch, T.; Preibisch, S.; Rueden, C.; Saalfeld, S.; Schmid, B.; et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods 2012, 9, 676–682. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  73. Szabad, G.; Kormos, B.; Pivarcsi, A.; Széll, M.; Kis, K.; Kenderessy Szabó, A.; Dobozy, A.; Kemény, L.; Bata-Csörgo, Z. Human adult epidermal melanocytes cultured without chemical mitogens express the EGF receptor and respond to EGF. Arch. Dermatol. Res. 2007, 299, 191–200. [Google Scholar] [CrossRef] [PubMed]
  74. Andrianne, M.; Assabban, A.; La, C.; Mogilenko, D.; Salle, D.S.; Fleury, S.; Doumont, G.; Van Simaeys, G.; Nedospasov, S.A.; Blackshear, P.J.; et al. Tristetraprolin expression by keratinocytes controls local and systemic inflammation. JCI Insight 2017, 2, 92979. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate: A Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 1995, 57, 289–300. [Google Scholar]
  76. Eden, E.; Navon, R.; Steinfeld, I.; Lipson, D.; Yakhini, Z. GOrilla: A tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinform. 2009, 10, 48. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  77. Eden, E.; Lipson, D.; Yogev, S.; Yakhini, Z. Discovering motifs in ranked lists of DNA sequences. PLoS Comput. Biol. 2007, 3, e39. [Google Scholar] [CrossRef]
Ijms 24 04556 g001 550
Figure 1. Schematic view of the experimental workflow. Abbreviations: 5-mC, 5-methylcytosine; 5-hmC, 5-hydroxymethylcytosine.
Figure 1. Schematic view of the experimental workflow. Abbreviations: 5-mC, 5-methylcytosine; 5-hmC, 5-hydroxymethylcytosine.
Ijms 24 04556 g001
Ijms 24 04556 g002 550
Figure 2. Confocal microscopy immunofluorescence analysis of 5-mC and 5-hmC in never-lesional vs. resolved skin. (a) Representative images are shown (n = 4). Colocalization immunofluorescence staining of 5-mC (green) and 5-hmC (red). Closeup images show yellow-dotted regions at higher magnification. Scale bars are 100 μm. (b) Real-time RT-PCR of TET1, TET2, and TET3 in resolved epidermis vs. never-lesional epidermis. An unpaired two-tailed t-test was performed, *** p < 0.001. Data = mean ± SEM of biological replicates (n = 3). Abbreviations: 5-mC, 5-methylcytosine; 5-hmC, 5-hydroxymethylcytosine; TET1, ten-eleven translocation (TET)1; TET2, ten-eleven translocation (TET)2; TET3, ten-eleven translocation (TET)3.
Figure 2. Confocal microscopy immunofluorescence analysis of 5-mC and 5-hmC in never-lesional vs. resolved skin. (a) Representative images are shown (n = 4). Colocalization immunofluorescence staining of 5-mC (green) and 5-hmC (red). Closeup images show yellow-dotted regions at higher magnification. Scale bars are 100 μm. (b) Real-time RT-PCR of TET1, TET2, and TET3 in resolved epidermis vs. never-lesional epidermis. An unpaired two-tailed t-test was performed, *** p < 0.001. Data = mean ± SEM of biological replicates (n = 3). Abbreviations: 5-mC, 5-methylcytosine; 5-hmC, 5-hydroxymethylcytosine; TET1, ten-eleven translocation (TET)1; TET2, ten-eleven translocation (TET)2; TET3, ten-eleven translocation (TET)3.
Ijms 24 04556 g002
Ijms 24 04556 g003 550
Figure 3. False-colored (pseudocolored) images of skin sections with a low magnification (20×) objective. All never-lesional and resolved pairs are identically brightness-adjusted. Scale bars are 250 μm. Abbreviations: 5-mC, 5-methylcytosine; 5-hmC, 5-hydroxymethylcytosine.
Figure 3. False-colored (pseudocolored) images of skin sections with a low magnification (20×) objective. All never-lesional and resolved pairs are identically brightness-adjusted. Scale bars are 250 μm. Abbreviations: 5-mC, 5-methylcytosine; 5-hmC, 5-hydroxymethylcytosine.
Ijms 24 04556 g003
Ijms 24 04556 g004 550
Figure 4. GO enrichment analysis of resolved vs. never-lesional epidermis DEGs. Enrichment shows only significant (a) BPs, (b) MFs, and (c) CCs with p < 0.05. Node color represents the specific functional class, biological processes, and cellular components involved in the enrichment analysis of the identified DEGs. Bold fonts indicate the major BPs, MFs, or CCs that define the names of each group. Abbreviations: DEG, differentially expressed genes; BPs, biological processes; MFs, molecular functions; CCs, cellular components.
Figure 4. GO enrichment analysis of resolved vs. never-lesional epidermis DEGs. Enrichment shows only significant (a) BPs, (b) MFs, and (c) CCs with p < 0.05. Node color represents the specific functional class, biological processes, and cellular components involved in the enrichment analysis of the identified DEGs. Bold fonts indicate the major BPs, MFs, or CCs that define the names of each group. Abbreviations: DEG, differentially expressed genes; BPs, biological processes; MFs, molecular functions; CCs, cellular components.
Ijms 24 04556 g004
Ijms 24 04556 g005 550
Figure 5. The Spearman’s rank correlation coefficient analysis was performed on 102 overlapping genes between 476 DEGs of the resolved vs. never-lesional and the 4104 DEGs of the lesional vs. healthy in epidermal compartments. The amount of change strongly correlated. Abbreviations: DEGs, differentially expressed genes.
Figure 5. The Spearman’s rank correlation coefficient analysis was performed on 102 overlapping genes between 476 DEGs of the resolved vs. never-lesional and the 4104 DEGs of the lesional vs. healthy in epidermal compartments. The amount of change strongly correlated. Abbreviations: DEGs, differentially expressed genes.
Ijms 24 04556 g005
Ijms 24 04556 g006 550
Figure 6. PPI networks of the 102 overlapping genes between resolved vs. never-lesional DEGs and lesional vs. healthy DEGs were generated using the STRING database. The figure shows the result ordered by network size. Abbreviations: PPI, protein–protein interaction; DEGs, differentially expressed genes.
Figure 6. PPI networks of the 102 overlapping genes between resolved vs. never-lesional DEGs and lesional vs. healthy DEGs were generated using the STRING database. The figure shows the result ordered by network size. Abbreviations: PPI, protein–protein interaction; DEGs, differentially expressed genes.
Ijms 24 04556 g006
Ijms 24 04556 g007 550
Figure 7. Mechanism of action of the three DEGs in resolved vs. never-lesional epidermis identified as likely to be important for lesion development in resolved epidermis. Significantly lower levels of the SAMHD1 gene in resolved epidermal keratinocytes might be accompanied by abnormal dNTP accumulation, which can induce DNA damage. It is established that damaged DNA species can trigger type-I IFN and innate immune responses. At the same time, SAMHD1 higher expression level in never-lesional epidermal keratinocytes may keep DNA integrity more efficiently. Strong up-regulation of GPR15L in resolved epidermal keratinocytes may lead to the recruitment of GPR15+ cells, such as T-cells, into the epidermal compartment. In resolved epidermal keratinocytes, the strong up-regulation of AKR1B10 gene may result in reduced RA and consequently increased keratinocytes survival and proliferation. However, the lower levels of AKR1B10 gene in never-lesional epidermal keratinocytes can activate the retinal–retinoic acid pathway and induce keratinocyte differentiation, while decreasing cell survival. Abbreviations: DEGs, differentially expressed genes; CoA, Coenzyme A; NADPH, nicotinamide adenine dinucleotide phosphate; dNTP, deoxynucleotide triphosphates; PPP, triphosphate; dN, deoxyribonucleoside.
Figure 7. Mechanism of action of the three DEGs in resolved vs. never-lesional epidermis identified as likely to be important for lesion development in resolved epidermis. Significantly lower levels of the SAMHD1 gene in resolved epidermal keratinocytes might be accompanied by abnormal dNTP accumulation, which can induce DNA damage. It is established that damaged DNA species can trigger type-I IFN and innate immune responses. At the same time, SAMHD1 higher expression level in never-lesional epidermal keratinocytes may keep DNA integrity more efficiently. Strong up-regulation of GPR15L in resolved epidermal keratinocytes may lead to the recruitment of GPR15+ cells, such as T-cells, into the epidermal compartment. In resolved epidermal keratinocytes, the strong up-regulation of AKR1B10 gene may result in reduced RA and consequently increased keratinocytes survival and proliferation. However, the lower levels of AKR1B10 gene in never-lesional epidermal keratinocytes can activate the retinal–retinoic acid pathway and induce keratinocyte differentiation, while decreasing cell survival. Abbreviations: DEGs, differentially expressed genes; CoA, Coenzyme A; NADPH, nicotinamide adenine dinucleotide phosphate; dNTP, deoxynucleotide triphosphates; PPP, triphosphate; dN, deoxyribonucleoside.
Ijms 24 04556 g007
Ijms 24 04556 g008 550
Figure 8. The DNA methylation/hydroxymethylation status of resolved vs. never-lesional epidermal keratinocytes. The DNA was hypo-methylated and hypo-hydroxymethylated in resolved vs. never-lesional epidermal keratinocytes. Hypo-methylated DNA is generally associated with open chromatin and transcription activation. Hence, the transcription might be more active in hypo-methylated DNA of resolved epidermal keratinocytes than never-lesional ones. Furthermore, hypo-methylated DNA in the resolved epidermis can reduce 5-hmC DNA levels. At the same time, the lower mRNA expression of TET3 enzyme might also be another reason for the loss of 5-hmC in the resolved epidermis. Abbreviations: 5-mC, 5-methylcytosine; 5-hmC, 5-hydroxymethylcytosine; TET3, ten-eleven translocation (TET)3.
Figure 8. The DNA methylation/hydroxymethylation status of resolved vs. never-lesional epidermal keratinocytes. The DNA was hypo-methylated and hypo-hydroxymethylated in resolved vs. never-lesional epidermal keratinocytes. Hypo-methylated DNA is generally associated with open chromatin and transcription activation. Hence, the transcription might be more active in hypo-methylated DNA of resolved epidermal keratinocytes than never-lesional ones. Furthermore, hypo-methylated DNA in the resolved epidermis can reduce 5-hmC DNA levels. At the same time, the lower mRNA expression of TET3 enzyme might also be another reason for the loss of 5-hmC in the resolved epidermis. Abbreviations: 5-mC, 5-methylcytosine; 5-hmC, 5-hydroxymethylcytosine; TET3, ten-eleven translocation (TET)3.
Ijms 24 04556 g008
Table
Table 1. The 25 most down-regulated and up-regulated DEGs in epidermal and dermal compartments. The 25 most down-regulated and up-regulated DEGs in resolved vs. never-lesional were sorted according to their FC. Abbreviations: DEG, differentially expressed genes; FC, fold of change.
Table 1. The 25 most down-regulated and up-regulated DEGs in epidermal and dermal compartments. The 25 most down-regulated and up-regulated DEGs in resolved vs. never-lesional were sorted according to their FC. Abbreviations: DEG, differentially expressed genes; FC, fold of change.
The 25 Most Down-Regulated and Up-Regulated Resolved vs. Never-Lesional DEGs in Epidermal and Dermal Compartments
Epidermis (n = 4)Dermis (n = 3)
Down-RegulatedUp-Regulated Down-RegulatedUp-Regulated
NumberGene SymbolFCGene SymbolFCNumberGene SymbolFCGene SymbolFC
1NEAT1_3−4.66STAC25.351SPRR4−32.61IGHV3-712.68
2SAMHD1−2.57AQP54.382ATP12A−25.92IGHV3-3310.90
3HOXB2−2.50FAM25C3.363CST6−17.10IGHJ410.56
4CACNA2D1−2.49ELOVL33.314SPRR1A−17.00IGKV3-207.39
5FHL1−2.22C10orf992.755CRCT1−14.41IGKV3-157.01
6RPL24P7−2.14AKR1B102.576MSMB−12.93IGLV1-446.40
7SNORA9−2.11FAM25G2.427KRT34−10.56POU6F26.10
8CYP4B1−2.05CRNN2.418GJB4−10.54IGKV1D-125.72
9ODF3L1−2.04RPL31P632.289RNF222−9.99LINC006195.61
10WNT2−2.03FABP5P22.2810CTSV−9.46ADH45.57
11KLHL11−1.94FABP5P102.2611KRTAP3-2−9.37IGKV1-175.03
12TMEM256−1.93LGR62.2012KRT33A−8.82IGKV1-124.87
13PELI2−1.88IL1F102.1913PLA2G2F−8.56IGHV2-704.69
14WDR82P2−1.88FABP5P12.1214SLC15A1−8.40ITIH14.49
15LIF−1.88FABP52.0915KRT31−8.30IGKV1-164.38
16TPPP−1.83WISP32.0916RPP21−8.29ADAM20P14.33
17RCAN2−1.77FABP5P72.0917TRIM39-RPP21−7.85SAA24.27
18PKIB−1.74NPM1P252.0718SPRR1B−7.48IGHV1-184.16
19MIR23A−1.71MRPS10P12.0719B4GALNT2−7.48RHPN1-AS14.10
20KLF9−1.68PYDC12.0320CASP1P2−7.15ANP32BP33.99
21LRRC8C−1.68IGFBP22.0021BPIFC−6.94RHOXF23.96
22SLC47A1−1.67RPS26P392.0022KRT38−6.89IGHV1-693.93
23CNTNAP3P2−1.66ENTPD31.9823LIPK−6.87OLAH3.89
24IKZF2−1.66KRT21.9424CARD18−6.43IGLV1-473.83
25WDR45BP1−1.66WNT5A1.9225PCSK1N−6.14MT33.79
Table
Table 2. KEGG pathway enrichment analysis was performed on the 102 overlapping genes between DEGs of the resolved epidermis vs. never-lesional epidermis and DEGs of the lesional epidermis vs. healthy epidermis. The results showed eight significantly enriched pathways (p < 0.001 and FDR < 0.2). Abbreviations: KEGG, Kyoto Encyclopedia of Genes and Genomes; DEGs, differentially expressed genes.
Table 2. KEGG pathway enrichment analysis was performed on the 102 overlapping genes between DEGs of the resolved epidermis vs. never-lesional epidermis and DEGs of the lesional epidermis vs. healthy epidermis. The results showed eight significantly enriched pathways (p < 0.001 and FDR < 0.2). Abbreviations: KEGG, Kyoto Encyclopedia of Genes and Genomes; DEGs, differentially expressed genes.
The KEGG Enrichment Analysis of the 102 Overlapping Genes between Resolved and Lesional Epidermis
Gene SetDescriptionSizeExpectRatiop ValueFDR
1hsa05217Basal cell carcinoma590.3875612.9013.78 × 10−50.0122
2hsa04550Signaling pathways regulating pluripotency of stem cells1320.867095.76641.63 × 10−30.1296
3hsa04310WNT signaling pathway1400.919645.43692.12 × 10−30.1296
4hsa05224Breast cancer1420.932775.36042.25 × 10−30.1296
5hsa05226Gastric cancer1420.932775.36042.25 × 10−30.1296
6hsa04150mTOR signaling pathway1440.945915.28592.39 × 10−30.1296
7hsa04916Melanogenesis950.624046.40993.36 × 10−30.1534
8hsa05225Hepatocellular carcinoma1601.0514.75733.78 × 10−30.1534
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Ghaffarinia, A.; Ayaydin, F.; Póliska, S.; Manczinger, M.; Bolla, B.S.; Flink, L.B.; Balogh, F.; Veréb, Z.; Bozó, R.; Szabó, K.; et al. Psoriatic Resolved Skin Epidermal Keratinocytes Retain Disease-Residual Transcriptomic and Epigenomic Profiles. Int. J. Mol. Sci. 2023, 24, 4556. https://doi.org/10.3390/ijms24054556

AMA Style

Ghaffarinia A, Ayaydin F, Póliska S, Manczinger M, Bolla BS, Flink LB, Balogh F, Veréb Z, Bozó R, Szabó K, et al. Psoriatic Resolved Skin Epidermal Keratinocytes Retain Disease-Residual Transcriptomic and Epigenomic Profiles. International Journal of Molecular Sciences. 2023; 24(5):4556. https://doi.org/10.3390/ijms24054556

Chicago/Turabian Style

Ghaffarinia, Ameneh, Ferhan Ayaydin, Szilárd Póliska, Máté Manczinger, Beáta Szilvia Bolla, Lili Borbála Flink, Fanni Balogh, Zoltán Veréb, Renáta Bozó, Kornélia Szabó, and et al. 2023. "Psoriatic Resolved Skin Epidermal Keratinocytes Retain Disease-Residual Transcriptomic and Epigenomic Profiles" International Journal of Molecular Sciences 24, no. 5: 4556. https://doi.org/10.3390/ijms24054556

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop